Opportunities and Limits of Sustainability
The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.
Contract Development And Manufacturing Organizations (CDMO)
Special Issue: Swiss CDMO Siegfried Celebrates 150th Anniversary
There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.
Sustainability – The Many Facets of Action
Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?
Siegfried Demonstrates Biologics Expertise in Hameln
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
"We Want to Be a Big Fish"
The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.
26.05.2023 • News
Olon Expands API Production
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.
04.05.2023 • News
CordenPharma Expands at US Site in Colorado
CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is designed to provide innovative biotech and pharma customers with a fully integrated API to Drug Product service offering.
13.04.2023 • News
WuXi STA Expands Capabilities at Changzhou Campus
WuXi STA has added two reactors at its Changzhou campus in China, enhancing capacity and capability at its TIDES contract research, development and manufacturing platform for oligonucleotide, peptide and related synthetic conjugates. The reactors have capacity of 2,000 liters each, taking total volume for solid-phase peptide synthesizers to more than 10,000 liters.
13.04.2023 • News
Catalent Starts Schorndorf Expansion
Catalent, a US-headquartered CDMO, has broken ground on a project in Schorndorf, Germany, that will add capacity for storing and handling clinical trial supply materials at controlled temperatures.
Delivering Quality with Speed for European Market
In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and the goals of the European expansion.
03.03.2023 • News
Aenova Appoints Hanno Scheffczik as Managing Director of its Marburg Site
Hanno Scheffczik has been appointed as the new Managing Director of Temmler Pharma, a member of the Aenova Group. Effective Mar. 1, 2023, he succeeds Alfred Veit, who is retiring.
22.02.2023 • Topics • Innovation
Axplora Aims to Make Pharmaceutical Supply Chains More Stable
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
20.02.2023 • News
Canada’s Biodextris Builds Biologics Facility
Canadian CDMO Biodextris plans to build a new industrial-scale vaccine and biologics facility in Laval, Quebec. The company said the cGMP biomanufacturing center and its analytical capabilities will be an asset in its development as a world-class CDMO.
13.02.2023 • News
Lotte Outlines Plans to Become Major CDMO Player
Lotte Biologics, part of South Korean conglomerate Lotte, has detailed expansions plans for the business as it embarks on a path to become a top 10 CDMO by 2030.
13.12.2022 • News
Catalent Opens Cell Therapy Facility in Belgium
Catalent has opened a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in Gosselies, Belgium.
07.12.2022 • News
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
06.12.2022 • News
Catalent Completes Shanghai Plant Expansion
US-headquartered CDMO giant Catalent has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
10.11.2022 • News
Change of Ownership for US CDMO Alcami
UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO Alcami from current private equity owners Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Financial terms of the deal were not disclosed.
02.11.2022 • News
Curia Begins Work on New Mexico Expansion
US CDMO Curia has begun construction on an expansion of its campus in Albuquerque, New Mexico. The facility designed by Burns & McDonnell will be built by BE&K Building Group.
31.10.2022 • News
Recipharm Bolsters Blow-Fill-Seal Capabilities in France
Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology.
27.10.2022 • News
Symeres Strengthens US Foothold with Exemplify Buy
Dutch CDMO Symeres has acquired Exemplify Biopharma, a US-based contract research organization (CRO) based in Cranbury, New Jersey, USA. The deal further strengthens Symeres’ foothold in the US, where it already generates about 50% of its revenues.
26.10.2022 • News
Catalent to Invest $12 Million at Kansas City
Catalent has announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
The Future of Outsourcing
The increasing complexity in drug development and the highly competitive industry landscape are creating a dramatic shift in how pharmaceutical and biotech companies plan for and execute drug development and production.
Investing in Growth Through Innovation
Interview with Marc Doyle, CEO of Arxada, which was created following the carve-out and sale of Lonza Specialty Ingredients to private equity firms Bain Capital and Cinven.
14.10.2022 • News
CDMO Adragos to Buy Sanofi Site in Japan
Munich-based German CDMO Adragos Pharma said it has signed a definitive agreement with Sanofi’s Japanese subsidiary to acquire a pharmaceutical manufacturing site in Kawagoe, near Tokyo.
14.10.2022 • News • Innovation
Bachem Innovates its Manufacturing Capabilities
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Ensuring API Supply Capacities for Europe and Beyond
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
23.09.2022 • News
Olon Expands Indian API Capabilities
Italian API producer Olon has announced plans to install a new high-containment production line at its site in Mahad, India.
31.08.2022 • News
Germany’s LTS Lohmann Buys US CDMO Tapemark
Germany’s LTS Lohmann Therapie-Systeme has completed the acquisition of St. Paul, Minnesota-headquartered CDMO Tapemark, a US specialist in transdermal drug delivery systems, oral thin films and unit dose semi-solid drug and iontophoresis products.
26.08.2022 • News
Arxada Expands at Visp to Continue Supplying DSM
Swiss specialty chemicals company Arxada said it will invest 20 million Swiss francs to expand production at its Visp site following the extension of a long-term supply partnership with DSM.
18.08.2022 • News
Rentschler Appoints Mark Caswell as Vice President, US Facility Site Head
Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.
18.07.2022 • News
Grace Expands Michigan Fine Chemicals Site
W. R. Grace is expanding its fine chemicals contract development and manufacturing facility in South Haven, Michigan, USA. The project is scheduled for completion in January 2024.
14.07.2022 • News
Fujifilm Invests $1.6 Billion for Cell Culture Expansion
Fujifilm is preparing to invest $1.6 billion to ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.
08.07.2022 • News
Lonza Builds Swiss Fill & Finish Facility
Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical drug product capabilities, will cost roughly 500 million Swiss francs and should be completed in 2026.
17.06.2022 • News
Expansion at SK Biotek API Plant to Cost $35 Miilion
South Korean CDMO SK Pharmteco (SKTP) said it will spend $35 million on the initial phase of a planned expansion at the Dublin, Ireland, API site the conglomerate acquired from Bristol Myers Squibb in 2017. Prior to that, SK had been a BMS supplier for around a decade.
